昂利康(002940) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥353,156,522.32, representing a 13.80% increase year-over-year, while the year-to-date revenue reached ¥986,885,462.15, up 7.47% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was ¥9,613,804.84, a significant decrease of 75.45% year-over-year, with a year-to-date net profit of ¥75,194,012.22, down 39.47% compared to the previous year[5] - The basic earnings per share for Q3 2021 was ¥0.1, down 77.27% year-over-year, while the diluted earnings per share also stood at ¥0.1, reflecting the same percentage decrease[5] - Total operating revenue for the third quarter reached ¥986,885,462.15, an increase of 7.4% compared to ¥918,248,206.67 in the same period last year[25] - Net profit for the period was ¥91,813,306.34, a decrease of 32.6% from ¥136,218,844.80 in the previous year[26] - Earnings per share (EPS) for the quarter was ¥0.78, down from ¥1.38 in the same quarter last year[27] Assets and Liabilities - The total assets as of September 30, 2021, were ¥1,896,558,214.32, a decrease of 2.28% from the end of the previous year[5] - Total liabilities decreased to ¥477,703,549.91 from ¥562,784,336.85, indicating a reduction of 15.1%[26] - Total assets stood at ¥1,896,558,214.32, down from ¥1,940,754,044.72, a decline of 2.3%[23] - The company's equity attributable to shareholders was ¥1,292,984,735.47, a slight decrease from ¥1,318,879,304.06[23] Cash Flow - The company reported a cash flow from operating activities for the year-to-date period of ¥155,946,945.13, down 13.65% compared to the previous year[5] - Cash generated from operating activities was ¥1,142,063,943.84, an increase of 10.6% from ¥1,032,880,810.74 in the prior year[28] - Net cash flow from operating activities was CNY 155,946,945.13, down from CNY 180,596,804.44 year-over-year[29] - Cash outflow from investing activities amounted to CNY 145,416,190.32, compared to CNY 89,807,824.18 in the same period last year[30] - Net cash flow from investing activities was negative at CNY -138,536,567.17, a decline from CNY 64,174,832.93 in the previous year[30] - Cash flow from financing activities showed a net outflow of CNY -130,561,802.81, compared to CNY -80,410,058.73 in the prior year[30] - The ending balance of cash and cash equivalents was CNY 733,663,744.32, down from CNY 614,874,919.60 year-over-year[30] Operating Costs and Expenses - The company experienced a 108.52% increase in operating costs, totaling ¥352,084,659.27, attributed to higher raw material costs due to increased sales[11] - Total operating costs amounted to ¥863,524,820.55, up 10.5% from ¥781,069,251.21 year-on-year[25] - Research and development expenses increased to ¥36,419,433.88, compared to ¥28,790,171.53 in the previous year, reflecting a growth of 26.5%[25] Investments and Shareholder Information - The company has increased its investment in construction projects, with construction in progress rising by 38.00% to ¥156,036,520.46, indicating ongoing expansion efforts[10] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., holds 35.44% of shares, totaling 34,000,000 shares[15] - The company has repurchased a total of 2,060,000 shares, accounting for 2.15% of the total share capital, with a total transaction amount of 63,330,916 RMB[17] - The company invested 40 million RMB in Jiaxing Yuanlai Yuanqi Venture Capital Partnership[17] - The company established a joint venture with Zhejiang Haichang Biopharmaceutical Technology Co., Ltd.[18] - The company increased its investment in Fujian Haixi United Pharmaceutical Co., Ltd. by 46.875 million RMB[19] Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 218.49% to ¥14,415,203.81, primarily due to increased advance payments for raw materials[10] - The company reported a significant increase in interest income to ¥20,495,291.91 from ¥13,738,659.56, marking a growth of 49.8%[26] - The company reported a 341.77% increase in asset impairment losses, amounting to ¥1,531,771.52, primarily due to inventory write-downs[12] - The company did not adjust the beginning balance sheet items due to the new leasing standards, as there were no leasing contracts prior to January 1, 2021[31] - The third-quarter report was not audited[32]